Eli Lilly and Co. has agreed to pay Dicerna Pharmaceuticals Inc. $100 million up front while investing $100 million more in the company as part of a new licensing and research collaboration agreement focused on the discovery, development and commercialization of medicines aimed at "more than 10 targets" in cardiometabolic disease, neurodegeneration and pain indications.